PROLAKTİNOMADA KABERGOLİN VE KALP KAPAK BOZUKLUKLARI

Year 2019, Volume: 52 Issue: 1, 83 - 86, 14.03.2019

Gül Gürsoy , Berrin Demirbaş Çarmıklı

Abstract

Kabergolin ergot türevi
dopamin agonisti olup hormon hipersekresyonu olan hipofiz tümörlerinde yaygın
olarak kullanılmaktadır. Parkinson hastalığında kabergolin
kullanımı, klinik olarak anlamlı kardiak kapak hastalığı gelişimi riski ile
ilişkili iken prolaktinoma ve akromegalide kabergolin tedavisi anlamlı valvulopati risk artışı ile ilişkili bulunmamıştır. Ayrıca  prolaktinomalarda  valvuler anormallik ile kabergolin kullanım
süresi veya kümülatif dozu arasında korelasyon gösterilmemiştir.

          Uzun dönem yüksek doz (>3 mg/hafta), kabergolin
tedavisi alan hastalarda valvüler anormallikleri göstermek için ekokardiografi ihtiyacı
varken, 1-2 mg/hafta dozunda kabergolin tedavisinde düzenli ekokardiografi ile
tarama gerekmez.

 

Keywords

Hipofiz tümörleri, kabergolin

References

• 1. Oolao O, Galderisi M, Di Sarno A, et al, Increased prevalance of tricuspid regurgitasyon in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008; 93:37777-84. 2. Auriemma RS, Pivonello R, Perone Y, Safely of long term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169:359-66. 3. Drake WM, Stiles CE. Howlett TA, A cross sectional study of the prevalance of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergo-derived dopamin agonists. Jclin Endocrinol Metab. 2014;99:90-6. 4. Renata S. Auremma , Pivonella Rosary, Lucia Ferrari et al, Cabergolin Use for pituitary tumors and valvular disorders. Endocrinol Metab Clin N Am.2015; 44: 89-97. 5. Borovac JA, Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini review of clinical pharmacology. Jale Journal of Biology and Medicine. 2016; 89:37-47. 6. Hutcheson D J, Vincent Setola, Bryan R et al, Serotonin Receptors and heart valve disease. It was meant 2B. Pharmacol Therapy. 2011; 132:146-57. 7. Michel A, Christophe Triboilloy, Drug-Induced valvular heart disease. An update. Archive of cardiovascular disease. 2013; 106:333-9. 8. Elenkova A, Shabani R, Kalinov K, Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012; 167: 17-25. 9. Lafeber M, Stades AME, Valk GD, Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinology. 2010;162:667-75. 10. Kars M, Pereia AM, Bax JJ, Cabergolin and cardiac valve disease in prolactinoma patients : additional studies during long term treatment are required. Eur J Endocrinol. 2008; 159:363-7. 11. Ammar W, Alan SR, Clark AL, Low dose cabergoline for hyperprolactinemia is not associated with clinicaly significant valvular heart disease. European J Endocrinol. 2008; 159: R11-4 12. Khare S, Lila AR, Patil R et al. Long- term cardiac (valvulopathy) safety of cabergoline in prolactinoma. Indian J Endocrinology Metab 2017; 21: 154–9. 13. Uz Ömer, Kaedeşoğlu E, Aparcı M, Özmen N, Cebeci BS, Kabergolinin neden olduğu hızlı gelişen mitral yetmezliği. Trakya Univ Tıp Fak Dergisi. 2008; 25:236-7. 14. Yamamoto M, Uesigu T, Nakayama T, Parkinson hastalığında dopamin agonistleri ve kardiak valvülopati. Neurology. 2006; 67:1225-9. 15. Lancellotti P, Livadariu E, Markov M, Cabergoline and the risk of valvular lesions in endocrine disease. European J of Endocrinology. 2008; 159: 1-5.